Pricing Log in Create free account

Lipocine Inc. (LPCN) vs Lisata Therapeutics, Inc. (LSTA)

Lipocine Inc. and Lisata Therapeutics, Inc. are both Biotechnology companies. Lipocine Inc. is the larger, with a market value of $12.6M against $10.7M — 1.2× the size. Lipocine Inc. grew revenue faster over the last twelve months: −13.4% against −24.7%. Lisata Therapeutics, Inc. has the higher net margin (0.00% vs −249.2%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Lipocine Inc. leads on 10 and Lisata Therapeutics, Inc. on 6.

Valuation

Metric LPCN LSTA Biotechnology median
P/E n/m n/m 10.26
P/S 3.37 0.60 9.18
P/B 0.60 1.15 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA 0.58 n/m 0.65
EV/Sales (1.58) 0.13 8.98
Earnings yield (88.89%) (162.38%) (34.89%)
Free cash flow yield (80.16%) (134.29%) (24.52%)

Profitability

Metric LPCN LSTA Biotechnology median
Gross margin 100.00% 0.49% 65.16%
Operating margin (269.05%) 0.00% 0.00%
Net margin (249.16%) 0.00% 0.00%
Free cash flow margin (267.37%) 0.00% 0.00%
Return on equity (52.86%) (101.66%) (50.12%)
Return on assets (47.52%) (80.81%) (45.60%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric LPCN LSTA Biotechnology median
Revenue growth (TTM) (13.36%) (24.67%) 6.26%
EPS growth (last fiscal year) (93,988.89%) 20.42% 29.88%
Revenue growth, 5-year CAGR 64.32% (20.28%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LPCN LSTA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 11.36 3.69 4.89
Net debt to EBITDA 1.42 0.88 1.01

Dividend

Metric LPCN LSTA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric LPCN LSTA Biotechnology median
Market cap 12.61m 10.71m 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack